<DOC>
	<DOC>NCT00809614</DOC>
	<brief_summary>This study is designed as a proof of concept of AIN457 in patients with psoriatic arthritis. The study will address the evaluation of the efficacy at 6 and up to 24 weeks after two doses of AIN457 10 mg/kg administered three weeks apart.</brief_summary>
	<brief_title>Efficacy of AIN457 in Adults (18-65 Years) With Psoriatic Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Psoriatic</mesh_term>
	<criteria>A diagnosis of psoriatic arthritis Patients with arthritis or ankylosing spondyitis Druginduced psoriasis Male or female patients who plan to conceive during the time course of the study, or for 6 months after the administration of the second dose. Participation in any clinical trial within 4 weeks prior to initial dosing or longer. Previous use of immunosuppressive agents eg cyclosporine, without the necessary washout period History of severe allergy to food or drugs Positive TB test. Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Psoriatic arthritis</keyword>
	<keyword>IgG1K monoclonal antibody</keyword>
	<keyword>Interleukin -17A neutralizing</keyword>
</DOC>